Breaking News

Merck Completes Acquisition of EyeBio

EyeBio, an ophthalmology-focused biotechnology company, is now a wholly-owned subsidiary of Merck.

Author Image

By: Charlie Sternberg

Associate Editor

Merck, known as MSD outside of the United States and Canada, has completed the previously announced acquisition of Eyebiotech Limited (EyeBio). EyeBio is now a wholly-owned subsidiary of Merck. “The EyeBio acquisition further diversifies our late-stage pipeline with the addition of a promising candidate based on novel biology and genetics for the treatment of certain retinal diseases,” said Dr. Dean Y. Li, president, Merck Research Laboratories. “We are excited to welcome the EyeBio team...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters